Cost-Effectiveness of Using Brentuximab Vedotin in Patients with Recurrent Hodgkin Lymphoma or Refractory to Transplant

Abstract

A 3 4 7 -A 7 6 6 A733 above was applied to the R-chemotherapy arm. Given the limited R-chemotherapy evidence and the immaturity of the available ibrutinib overall survival (OS) data, post-progression survival (PPS) was assumed equal in the two arms. OS was the sum of PFS + PPS. Utility data were taken from the pooled ibrutinib dataset and a utility decrement for patients while receiving chemotherapy was applied as per expert opinion4. Results: Estimated outcomes for ibrutinib were 2.28 life years (LYs) and 1.59 QALYs per patient. R-chemotherapy resulted in 1.04 LYs and 0.65 QALYs using the fist method and 1.26 LYs and 0.77 QALYs using the second method. ConClusions: The limited evidence available in R/R MCL inhibits a direct comparison between ibrutinib and R-chemotherapy. Modelled estimates using available data indicate that ibrutinib offers a large QALY and LY benefit versus R-chemotherapy.